Ockham, a Cary-based contract research organization, has acquired Nexus Oncology in a move that will more strongly position the company to conduct drug development clinical trials of all sizes.
The acquisition brings Ockham's total number of employees to 300 spread across 12 countries and will strengthen the company's focus on oncology research.
"The experience of the Nexus clinical team and their leadership will help the newly enlarged company to expand our services and be a force in getting lifesaving drugs to market more efficiently," said James Baker, Ockham's CEO.
Nexus Oncology was founded in 1999 and provides clinical research services to biopharmaceutical companies developing cancer treatments. It has 120 employees globally.
The combined company will operate under the name Ockham and will be led by Baker. Clare Wareing, founder of Nexus, will serve as chief scientific officer, and the Ockham's board of directors will have representation from both companies.